Federal Register / Vol. 72, No. 19 / Tuesday, January 30, 2007 / Notices 4273 

and sharing of lessons learned. They are 

world leaders in this area and have 

worked with other programs in similar 

settings to improve chronic illness 

systems of care for underserved and 

vulnerable populations, including the 

Health Resources and Services 

Administration/Bureau of Primary 

Health Care’s health center program for 

eight years. The IHI’s intellectual capital 

and operational capacity are essential to 

the IHS. The IHI has the resources and 

access to an international network of 

experts in the area of chronic disease 

management and implementing chronic 

care models in various settings. Most 

other improvement agencies and 

organizations focus on specific steps 

and methodologies while IHI takes a 

much more comprehensive and strategic 

approach to improvement. Over the past 

15 years they have become the 

recognized world leader in system 

change in healthcare. They have moved 

beyond the specifics of software into 

process development using a variety of 

techniques to make the best use of 

technologies and existing organizational 

capabilities. Their methodologies 

include improvement advisors who act 

as peer to peer coaches for organizations 

implementing change. This personal 

approach and the IHI’s considerable 

expertise are critical to expand existing 

Indian Country efforts, where personal 

connection and effective relationships 

are often the difference between project 

success and failure. 

This single source cooperative 

agreement will allow IHS to expedite 

learning from their organization as well 

as expedite access to IHI’s vast network 

of strategic partners. 

III. Award Information 

Type of Awards: Cooperative 

Agreement. 

Estimated Funds Available: The 

award is for three years. For year one 

$600,000 is available and for years two 

and three—$800,000 is available for 

each year for a continuation award. 

Award under this announcement is 

subject to availability of funds. 

Anticipated Number of Awards: One 

single source award will be made under 

the Program. 

Project Period: February 16, 2007–

February 15, 2010. 

Award Amount: $600,000 in year 1; 

$800,000 in years 2 and 3. 

For information regarding the 

notification, please contact: Candace M. 

Jones, MPH, National Programs 

(NPABQ), 5300 Homestead Road, NE., 

Albuquerque, NM 87110, 505–248–4961 

or candace.jones@ihs.gov. 

Electronic Submission: The preferred 

method for receipt of applications is 

electronic submission through 

Grants.gov. Please refer to the following 

links for complete application 

instructions: applicant package may be 

found in Grants.gov (www.grants.gov) or 

http://www.ihs.gov/ 

NonMedicalPrograms/gogp/ 

gogplfund.asp. 

Dated: January 18, 2007. 

Robert G. McSwain, 

Deputy Director, Indian Health Service. 

[FR Doc. 07–386 Filed 1–29–07; 8:45 am] 

BILLING CODE 4165–16–M 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

The National Institutes of Health 

Proposed Collection; Comment 

Request; Monitoring and Evaluation of 

the NIDA Goes Back to School 

National Dissemination Campaign 

Summary: In compliance with Section 

3506(c)(2)(A) of the Paperwork 

Reduction Act of 1995 concerning 

opportunity for public comment on 

proposed collection of information, the 

National Institute on Drug Abuse 

(NIDA), the National Institutes of Health 

(NIH) will publish periodic summaries 

of proposed projects to be submitted to 

the Office of Management and Budget 

(OMB) for review and approval. 

Proposed Collection: Title: Monitoring 

and Evaluation of the NIDA Goes Back 

to School National Dissemination 

Campaign. Type of Information 

Collection Request: New. Need and Use 

of Information Collection: This is a 

request for a one-time clearance to 

collect information on the use of the 

NIDA Goes Back to School (NGBTS) 

dissemination materials that can be 

requested by interested persons from the 

NIDA Internet site. The National 

Institute on Drug Abuse (NIDA) 

launched an initiative to increase 

awareness of the Institute and its 

mission to bring the power of science to 

bear on the treatment and prevention of 

drug abuse and addiction. NIDA has 

been developing science education 

materials for grades K–12 for use by 

students, teachers, parents, school 

counselors, school health educators, 

school resources officers, community 

organizers, and state and local 

government agencies. The number of 

requestors has been an average of 7,500 

per year. These large numbers indicate 

that the dissemination reach is 

considerable. The pattern of requests 

also indicates that the number of 

requests increases dramatically in the 

early weeks after a dissemination 

activity is launched. The purpose of this 

information collection is to determine 

the level of use by school personnel and 

community leaders who request the 

NGBTS materials, and if there is a 

difference in use level between those 

requestors responding to a campaign 

activity and those requestors who were 

not reached by campaign activities. The 

information will identify barriers to the 

use of the materials among these 

occupational groups and the 

populations they serve. It will help 

make the materials more productive in 

raising the awareness of the harms from 

substance abuse among children, youth, 

and parents. It will be used to refine the 

focus of the dissemination activities, so 

that dissemination resources are used 

more productively. The information will 

be collected from requestors who have 

requested NIDA NGBTS materials using 

the requestor forms from the NIDA site, 

from October 2003 to September 2005. 

All information collection in the 

evaluation will be conducted on-line. 

The estimated total time for a survey is 

5 minutes. Prior to the monitoring and 

evaluation study, the information 

collection instruments will be pilottested via telephone interview format, 

with a sample of 8 individuals who 

have requested these materials during 

the chosen study years. The surveys will 

include the following elements: (1) Use 

of the NGBTS materials, (2) Opinion of 

the NGBTS materials, (3) Respondent 

information on gender, present 

occupation and its duration, (4) 

Background information on the school 

or Organization/Community. Frequency 

of Response: This project will be 

conducted once. Affected Public: School 

personnel, and Community Leaders who 

have requested the NGBTS materials. 

Type of Respondent: School personnel, 

and Community Leaders who have 

requested the NGBTS materials from the 

NIDA site. Estimated Total Annual 

Number of Respondents: 400. Estimated 

Number of Responses per Respondent: 

1. Average Burden Hours per Response: 

.08. Estimated Total Annual Burden 

Hours Requested: 32.0. There are no 

Capital Costs to report. There are no 

Operating or Maintenance Costs to 

report. The estimated annualized 

burden is summarized below. 


ycherry on PROD1PC64 with NOTICES
4274 Federal Register / Vol. 72, No. 19 / Tuesday, January 30, 2007 / Notices 

Type of respondents Number of 

respondents 

Frequency of 

response 

Average burden 

hours per 

response 

Estimated 

total burden 

hours requested 

Requesters—School Personnel ....................................................... 200 1 0.08 16 

Requestors—Community Leaders ................................................... 200 1 0.08 16 

Total .......................................................................................... 400 ............................ ............................ 32 

Request for Comments: Written 

comments and/or suggestions from the 

public and affected agencies are invited 

on one or more of the following points: 

(1) Whether the proposed collection of 

information is necessary for the proper 

performance of the functions of the 

agency, including whether the 

information shall have practical utility; 

(2) the accuracy of the agency’s estimate 

of the burden of the proposed collection 

of information; (3) ways to enhance the 

quality, utility, and clarity of the 

information to be collected; and (4) 

ways to minimize the burden of the 

collection of information on 

respondents, including through the use 

of automated collection techniques or 

other forms of information technology. 

FOR FURTHER INFORMATION CONTACT: To 

request more information on the 

proposed project or to obtain a copy of 

the information collection plans, contact 

Brian Marquis, Project Officer, National 

Institute on Drug Abuse, 6001 Executive 

Boulevard, Room 5216, Bethesda, MD 

20892, or call non-toll-free number 301–

443–1124; fax 301–443–7397; or by email to bmarquis@/nida.nih.gov. 

Comments Due Date: Comments 

regarding this information collection are 

best assured of having their full effect if 

received within 60-days of the date of 

this publication. 

Donna Jones, 

Budget Officer & Acting Associate Director 

for Management, National Institute on Drug 

Abuse. 

[FR Doc. 07–357 Filed 1–29–07; 8:45 am] 

BILLING CODE 4140–01–M 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

Government-Owned Inventions; 

Availability for Licensing 

AGENCY: National Institutes of Health, 

Public Health Service, HHS. 

ACTION: Notice. 

SUMMARY: The inventions listed below 

are owned by an agency of the U.S. 

Government and are available for 

licensing in the U.S. in accordance with 

35 U.S.C. 207 to achieve expeditious 

commercialization of results of 

federally-funded research and 

development. Foreign patent 

applications are filed on selected 

inventions to extend market coverage 

for companies and may also be available 

for licensing. 

ADDRESSES: Licensing information and 

copies of the U.S. patent applications 

listed below may be obtained by writing 

to the indicated licensing contact at the 

Office of Technology Transfer, National 

Institutes of Health, 6011 Executive 

Boulevard, Suite 325, Rockville, 

Maryland 20852–3804; telephone: 301/ 

496–7057; fax: 301/402–0220. A signed 

Confidential Disclosure Agreement will 

be required to receive copies of the 

patent applications. 

Megakaryocyte Potentiation Factor as a 

New Serum Tumor Marker for 

Mesothelioma 

Description of Technology: 

Mesothelin is a glycoprotein, whose 

expression has been largely restricted to 

mesothelial cells in normal tissues, 

although epithelial cells of the trachea, 

tonsil, fallopian tube, and kidney have 

shown immunoreactivity. Mesothelin 

has been shown to be expressed in 

several cancers including mesothelioma, 

lung cancer, pancreatic carcinomas, 

gastric carcinomas and ovarian 

carcinomas, and has the potential of 

being used as a tumor marker and a 

novel target for the development of new 

treatments. 

Mesothelin precursor protein is a 69 

kDa protein that is proteolytically 

cleaved into two products, the 

megakaryocyte potentiation factor 

(MPF) and mesothelin. MPF is a 33 kDa 

soluble protein that is shed into the 

blood stream of patients with 

mesotheliomas and other tumors 

including ovarian and pancreatic and 

thus can be used as a serum marker for 

the diagnosis of mesothelin expressing 

cancers. 

This invention describes the 

generation of monoclonal antibodies to 

MPF. The antibodies can be useful for 

diagnosing mesotheliomas and other 

cancers. Additionally, it can be used by 

the oncological research community as 

a research tool. 

Applications: New monoclonal 

antibodies against MPF; A new 

monoclonal antibody against MPF that 

can be used for diagnosis method for 

mesotheliomas and other cancers 

including ovarian and pancreatic by 

detecting MPF in serum of patients. 

Market: Cancer diagnostic market is 

projected to grow to approximately $8B 

in the next 5 years; Potential as a 

research tool for oncology research 

market. 

Inventor: Ira H. Pastan et al. (NCI). 

Publication: M Onda et al. 

Megakaryocyte potentiation factor 

cleaved from mesothelin precursor is a 

useful tumor marker in the serum of 

patients with mesothelioma. Clin 

Cancer Res. 2006 Jul 15;12 (14 Pt 

1):4225–4231. 

Patent Status: HHS Reference No. E–

293–2006/0—Research Tool. 

Licensing Status: Available for 

licensing under a Biological Materials 

license. 

Licensing Contact: Jesse S. Kindra, 

J.D.; 301/435–5559; 

kindraj@mail.nih.gov. 

Enriched Natural Killer Cells for 

Adoptive Infusion Cancer Therapy 

Description of Technology: Immunotherapy has taken a lead among the new 

cancer therapeutic approaches. It is one 

of the most promising new therapeutic 

approaches that exploit the innate 

immune mechanism of an individual to 

fight against a certain disease. 

Natural killer (NK) cells are a form of 

cytotoxic lymphocytes which constitute 

a major portion of the innate immune 

system. NK cells have tumor cytotoxic 

properties independent of tumor 

specific antigens and have been shown 

in murine models to control and prevent 

tumor growth and dissemination. 

Inactivation of NK cells potentially 

allows cancer cells to evade host NKcell-mediated immunity. Ligation of 

killer immunoglobulin like receptors 

(KIRs) by MHC class I on both normal 

and malignant tissues suppresses the 

function of NK cells. 

The present invention relates to 

treating cancer and other 

hyperproliferative disorders by 

administering an enriched composition 

of allogeneic or autologous (KIR/KIR 

ligand incompatible) NK cell 

population. This enriched composition 

can potentially override the inactivation 


ycherry on PROD1PC64 with NOTICES